GE Healthcare, an integral part of General Electric Company (GE), recently announced that it has received the European Union’s approval for marketing its VIZAMYL (Flutemetamol (18F) Solution for Injection). VIZAMYL is a radiopharmaceutical medicinal product for Positron Emission Tomography (PET) imaging of beta amyloid plaque in brains of adult patients suffering from cognitive diseases. VIZAMYL will enable patients to get a neurological diagnosis of diseases such as Alzheimer’s (AD).
General Electric’s VIZAMYL is the only diagnostic PET imaging tracer approved in the Euproean Union for detection of beta amyloid and visual interpretation of colour images. Along with the commercial launch of VIZAMYL in early 2015, GE Healthcare has also developed a mandatory electronic reader training program (ETP) for readers of VIZAMYL images.
GE Healthcare provides transformational medical technologies and services by ensuring greater access to enhanced quality and affordable healthcare facilities across the globe. The approval is likely to further expand the scope of innovative diagnostic technologies for more accurate assessment of specific patients evaluated for Alzheimer’s disease and support further research into the required disease modifying agents.
General Electric, the parent company of GE Healthcare, is one of the most diversified technologies and financial service corporations in the world. Its segments include Power & Water, Oil & Gas, Energy Management, Aviation, Healthcare, Transportation, Home & Business Solutions, and GE Capital.
General Electric currently has a Zacks Rank #3 (Hold). Other stocks that look promising in the industry include Federal Signal Corp. (FSS), Macquarie Infrastructure Company LLC. (MIC) and ITT Corporation (ITT), each having a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment